If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

October 3, 2016 | A version of this story appeared in Volume 94, Issue 39

BASF will replace the acetylene plant at its headquarters site in Ludwigshafen, Germany, with a new 90,000-metric-ton-per-year plant by the end of 2019. Some 20 facilities at the site use acetylene as a starting material, BASF says.

Clariant plans its first hair care competence center, near São Paulo, Brazil. To open early next year, the 240-m2 facility will house applications and formulations labs. Clariant says 20% of growth in the hair care market comes from Brazil.

Givaudan has opened a clove leaf oil processing plant in Madagascar. The facility will take in hundreds of metric tons of clove leaf oil a year from local farmers and convert it into derivatives such as eugenol for flavors and fragrances, the firm says.

Cool Planet has raised $9 million from investors to commercialize its Cool Terra Engineered Biocarbon. The Colorado-based firm was founded in 2009 to make fuel from biomass via pyrolysis but has refocused on a by-product of the process that can be added to soil to trap nutrients.

BASF Chairman Kurt Bock has been elected chairman of the German Chemical Industry Association (VCI) for a two-year term. Bock previously served a two-year stint as president of the European Chemical Industry Council (Cefic) beginning in 2013.

Monsanto will license CRISPR/Cas genome-editing technology for use in agriculture from the Broad Institute of MIT & Harvard. The nonexclusive agreement gives Monsanto access to several patents that it will use to improve crops.

Selvita, a Polish contract research organization, has signed a deal to buy land in Kraków, Poland, where it plans to build new laboratories. The firm says the site is close to its current facilities and could accommodate a laboratory-office complex for about 1,000 employees.

Fortis Therapeutics has launched with $18 million in financing to develop antibody-drug conjugates. Fortis’s technology came out of the labs of University of California, San Francisco, professor Bin Liu, who discovered a receptor that is overexpressed in many people with late-stage prostate cancer.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.